Biomerica, Inc. reported net sales of $5.3 million for the fiscal year ended May 31, 2025, a modest decrease from $5.4 million in the prior year. This decline was attributed to global tariff-related uncertainties, which caused certain international customers to delay orders, and a shift in product mix with fewer over-the-counter (OTC) retail sales during the fourth quarter. These headwinds were partially offset by increased sales from the inFoods IBS product.
Despite the revenue dip, the company demonstrated disciplined cost management, significantly improving cash used in operating activities to $3.8 million, compared to $5.3 million in the prior year, a $1.5 million improvement. Selling, general, and administrative expenses were reduced to $4.6 million from $5.5 million, and research and development expenses decreased to $1.0 million from $1.5 million. In total, operating expenses declined by over $1.3 million, delivering on announced cost-reduction goals.
As a result of these efforts, the operating loss improved by 19% year-over-year, narrowing to $5.1 million from $6.4 million in the prior year. Key milestones achieved in fiscal year 2025 included the submission of a Proprietary Laboratory Analysis (PLA) code application for inFoods IBS, peer-reviewed validation of inFoods IBS clinical study results in *Gastroenterology*, and EU IVDR certification for Crohn’s disease and ulcerative colitis diagnostic tests. The company also expanded its presence in the Middle East with regulatory approvals for Fortel PSA and launched direct-to-consumer availability for inFoods IBS, alongside intellectual property growth and advancement of the inFoods IBS patient self-collection system.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.